Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + liposomal doxorubicin + etoposide + methylprednisolone
- Development stage
- Unknown
- Lead developer
- Beijing Friendship Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
DEP-Ru is a **co-administration salvage regimen** for refractory or relapsed hemophagocytic lymphohistiocytosis comprising oral ruxolitinib plus liposomal doxorubicin, etoposide, and methylprednisolone. Ruxolitinib inhibits JAK1 and JAK2 to suppress cytokine-driven hyperinflammation, while liposomal doxorubicin and etoposide provide cytotoxic and topoisomerase II-directed activity and methylprednisolone provides glucocorticoid-mediated immunosuppression. Beijing Friendship Hospital, Capital Medical University evaluated the regimen in a multicenter, single-arm phase 2 trial for refractory or relapsed hemophagocytic lymphohistiocytosis.
- Other names
- DEP-RuDEP-ruxolitinibRu-DEP
02
Targets
JAK2 (Janus kinase 2)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNAJAK1 (Janus kinase 1)
Beyond the preview
Go deeper on ruxolitinib + liposomal doxorubicin + etoposide + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + liposomal doxorubicin + etoposide + methylprednisolone.